Nanomedicines: A new approach for the treatment of serious diseases

Journal of Biomedical Nanotechnology

Volumn 3, Issue 3, 2007, Pages 223-234

  Vauthier, Christine ^a   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Bioavailability; Biodistribution; Cancer; Chemotherapy; Drug targeting; Infections; Nanocapsules; Nanoparticles

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ALBUMIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIESTROGEN; ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CALCITONIN; CHITOSAN; CHLOROQUINE; DOXORUBICIN; DOXORUBICIN TRANSDRUG; GEMCITABINE; HALOFANTRINE; INSULIN; LIPOSOME; MACROGOL; NANOCAPSULE; NANOPARTICLE; PACLITAXEL; PEPTIDE DERIVATIVE; POLYAKLYLCYANOACRYLIC ACID; POLYCYANOACRYLIC ACID; POLYISOHEXYLCYANOACRYLIC ACID; POLYMER; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; TAMOXIFEN; UNINDEXED DRUG; VERAPAMIL;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MEGADOSE; DRUG PACKAGING; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; IN VIVO STUDY; INFECTION; LIVER CELL CARCINOMA; MALARIA; MATERIAL COATING; METASTASIS; MULTIDRUG RESISTANCE; NANOBIOTECHNOLOGY; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PARTICLE SIZE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 44749085632     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2007.038     Document Type: Review

References (112)

1. I. Brigger, C. Dubernet, and P. Couvreur, Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631 (2002).
2. P. Couvreur, G. Barratt, E. Fattal, P. Legrand, and C. Vauthier, Nanocapsule technology: A review. Crit. Rev. Ther. Drug. Carrier Syst. 19, 99 (2003).
3. M. J. Alonso, Nanomedecine for overcoming biological barriers. Biomedicine and Pharmacotherapy 58, 168 (2004).
4. J. K. Vasir, M. K. Maram, and V. D. Labhasetwar, Nanosystems in drug targeting: Opportunities and challenges. Current Nanoscience 1, 47 (2005).
5. P. Couvreur and C. Vauthier, Nanotechnology: Intelligent design to treat complex desease. Pharm. Res. 23, 1417 (2006).
6. S. M. Moghimi, Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. Anticancer Agents Med. Chem. 6 553 (2006).
7. V. P. Torchilin, Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532 (2006).
8. T. K. Vyas, L. Shah, and M. M. Amiji, Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv. 3, 613 (2006).
9. T. Minko, R. I. Pakunlu, Y. Wang, J. J. Khandare, and M. Saad, New generation of liposomal drugs for cancer. Anticancer Agents Med. Chem. 6, 537 (2006).
10. S. P. Vyas and K. Khatri, Liposome-based drug delivery to alveolar macrophages. Expert Opin. Drug Deliv. 4, 95 (2007).
11. B. Angelov, A. Angelova, B. Papahajopoulos-Sternberg, S. Lesieur, J. F. Sadoc, M. Ollivon, and P. Couvreur, Detailed structure of diamond type lipidic cubic nanoparticles. J. Amer Chem. Soc. 128, 5813 (2006).
12. F. Sonvico, C. Dubernet, P. Colombo, and P. Couvreur, Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm. Design 11, 2095 (2005).
13. M. Di Marco, M. Port, P. Couvreur, C. Dubernet, P. Ballirano, and C. Sadun, Structural characterization of ultrasmall superparamagnetic iron oxide (USPIO) particles in aqueous suspension by energy dispersive X-ray diffraction (EDXD). J Am. Chem. Soc. 128, 10054 (2006).
14. S. K. Sahoo, V. Labhasetwar, Nanotech approaches to drug delivery and imaging. Drug Discov. Today 8, 1112 (2003).
15. G. Barratt, Colloidal drug carriers: Achievements and perspectives. Cell. Mol. Life Sci. 60, 21 (2004).
16. S. M. Moghimi, A. C. Hunter, and J. C. Murray, Nanomedicine: Current status and future prospects. FASEB J. 19, 311 (2005).
17. C. Pegro, M. Garcia, D. Torres, and M. J. Alonso, Transmucosal macromolecular drug delivery. J. Controlled Rel. 101, 151 (2005).
18. H. R. Kim, K. Andrieux, S. Gil, M. Taverna, H. Chacun, D. Desmaële, F. Taran, D. Georgin, and P. Couvreur, Translocation of PEGylated nanoparticles into rat brain endothelial cells: Role of apolipoproteins on receptor mediated endocytosis. Biomacromolecules (2007), Vol. 8, pp. 793-799.
19. G. Lambert, E. Fattal, and P. Couvreur, Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv. Drug Deliv. Rev. 47, 99 (2001).
20. G. S. Kwon, Polymeric micelles for the delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst. 20, 357 (2003).
21. J. Panyam and J. Labhasetwar, Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329 (2003).
22. A. El-Aneed, An overview of current delivery systems in cancer gene therapy. J. Control. Release 94, 1 (2004).
23. V. P. Torchilin, Targeted polymeric micelles for delivery of poorly soluble drugs. Cell. Mol. Life Sci. 61, 2549 (2004).
24. G. Gaucher, M. H. Dufresne, V. P. Sant, N. Kang, D. Maysinger, and J. C. Leroux, Block copolymer micelles: Preparation, characterization and application in drug delivery. J. Control. Release 109, 169 ( 2005).
25. S. Kommareddy, S. B. Tiwari, and M. M. Amiji, Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol. Cancer Res. Treat. 4, 615 (2005).
26. N. Toub, C. Mavy, E. Fattal, and P. Couvreur, Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed. Pharmacother. 60, 607 (2006).
27. V. P. Torchilin, Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 24, 1 (2007).
28. J. Kattan, J. P. Droz, P. Couvreur, J. P. Marino, A. Boutan-Laroze, P. Rougier, P. Brault, H. Vranckx, J. M. Grognet, X. Morge, and H. Sancho-Garnier, Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 10, 191 (1992).
29. J. F. Dufour-Lamartinie, F. Habersetzer, A. Abergel, P. Merle, S. I. Si Ahmed, L. Bonyhay, J. Taieb, D. Costantini, and C. Trepo, Phase 1 study of intra-arterial hepatic (iah) delivery of doxorubicin-transdrug® (dt) for patients with advanced hepatocellular carcinoma (hcc). Abstract to the 12th International Symposium on Viral Hepatitis and Liver Disease, Paris, France. Supp. J. Clin. Virol. 36 (Suppl. 2) (2006).
30. V. Roy and E. A. Perez, New therapies in the treatment of breast cancer. Semin. Oncol. 33, S3 (2006).
31. D. E. Owens, 3rd and N. A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93 (2006).
32. A. Vonabourg, C. Passirani, P. Saulnier, and J. P. Benoit, Parameters influencing the stealthiness of colloidal drug delivery systems. Biomatierials 27, 4356 (2006).
33. I. Bertholon, C. Vauthier, and D. Labarre, Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: Influences of surface morphology, length, and type of polysaccharide. Pharm. Res. 23, 1313 (2006).
34. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer, Biodegradable long-circulating polymeric nanospheres. Science 263, 1600 (1994).
35. M. T. Peracchia, C. Vauthier, C. Passirani, P. Couvreur, and D. Labarre, Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci. 61, 749 (1997).
36. M. T. Peracchia, C. Vauthier, D. Desmaël, A. Gulik, J. C. Dedieu, M. Demoy, J. D'Angelo, and P. Couvreur, Pegylated nanoparticles from a novel methoxypolyethyleneglycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm. Res. 15, 550 (1998).
37. R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, and R. H. Muller, 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf., B. Biointerfaces 18, 301 (2000).
38. P. Couvreur, B. Kante, V. Lenaerts, L. Deckers-Passau, and M. Roland, Tissue distribution if antitumor drugs associated with polyalkylcyanoacrylate nanoparticules. J. Pharm. Sci. 69, 199 ( 1980).
39. C. Verdun, F. Brasseur, H. Vranckx, P. Couvreur, and M. Roland, Tissue distribution of doxorubicin associated with polyisohexyl-cyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26, 13 (1990).
40. C. Passirani, G. Barratt, J. P. Devissaguet, and D. Labarre, Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res. 15, 1046 (1998).
41. M. K. Basu and S. Lala, Macrophage specific drug delivery in experimental leishmaniasis. Curr. Mol. Med. 4, 681 (2004).
42. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control. Release 65, 271 (2000).
43. P. Calvo, B. Gouritin, I. Brigger, C. Lasmezas, J. Deslys, A. Williams, J. P. Andreux, D. Dormont, and P. Couvreur, PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neurosci. Methods 111, 151 (2001).
44. P. Calvo, B. Gouritin, H. Villarroya, F. Eclancher, C. Giannavola, C. Klein, J. P. Andreux, and P. Couvreur, Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 15, 1317 (2002).
45. I. Brigger, J. Morizet, G. Aubert, H. Chacun, M. J. Terrier-Lacombe, and P. Couvreur, Poly(ethylene glycol)-coated hexade-cylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Therap. 303, 928 (2002).
46. P. Calvo, B. Gouritin, H. Chacun, D. Desmaele, J. D'Angelo, J. P. Noel, D. Georgin, E. Fattal, J. P. Andreux, and P. Couvreur, Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157 (2001).
47. J. Kreuter, Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci. Nanotechnol. 4, 484 (2004).
48. R. H. Muller and C. M. Keck, Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol. 4, 471 (2004).
49. S. V. Vinogradov, E. V. Batrakova, and A. V. Kabanov, Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 15, 50 ( 2004).
50. E. Garcia-Garcia, K. Andrieux, S. Gil, and P. Couvreur, Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int. J. Pharm. 298, 274 (2005).
51. J. C. Olivier, Drug transport to brain with targeted nanoparticles. NeuroRx. 2, 108 (2005).
52. E. Garcia-Garcia, S. Gil, K. Andrieux, D. Desmaele, V. Nicolas, F. Taran, D. Georgin, J. P. Andreux, F. Roux, and P. Couvreur, A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell. Mol. Life Sci. 62, 1400 (2005).
53. E. Garcia-Garcia, K. Andrieux, S. Gil, H. R. Kim, T. Le Doan, D. Desmaele, J. d'Angelo, F. Taran, D. Georgin, and P. Couvreur, A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int. J. Pharm. 298, 310 (2005).
54. H. R. Kim, S. Gil, K. Andrieux, V. Nicolas, M. Appel, H. Chacun, D. Desmaele, F. Taran, D. Georgin, and P. Couvreur, Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell. Mol. Life Sci. 64, 356 (2007).
55. M. Youssef, E. Fattal, M. J. Alonso, L. Roblot-Treupel, J. Sauzières, C. Tancrède, A. Omnès, P. Couvreur, and A. Andremont, Effectiveness of nanoparticle-bound ampicillin in treatment of Listeria Monocytogenes infection in athymic nude mice. Antimicr. Agents Chemother. 32, 1204 (1988).
56. O. Balland, H. Pinto-Alphandary, S. Pecquet, A. Andremont, and P. Couvreur, Intracellular uptake and activity of ampicillin-loaded nanoparticles on murine macrophages infected by Salmonela Typhimurium. J. Antimicr. Chemother. 33, 509 (1994).
57. S. Gomez, Ph.D. Thesis, Gantrez® AN nanoparticles for allergen immunotherapy. University of Navarre, Pamplona, Spain (2006).
58. R. Gref, P. Couvreur, G. Barratt, and E. Mysiakine, Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 24, 4529 (2003).
59. L. Nobs, F. Buchegger, R. Gurny, and E. Allemann, Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 93, 1980 (2004).
60. L. Nobs, F. Buchegger, R. Gurny, and E. Allemann, Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug. Chem. 17, 139 (2006).
61. B. Stella, S. Arpicco, M. T. Peracchia, D. Desmaele, J. Hoebeke, M. Renoir, J. D'Angelo, L. Cattel, and P. Couvreur, Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89, 1452 (2000).
62. A. R. Hilgenbrink and P. S. Low, Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J. Pharm. Sci. 94, 2135 (2005).
63. E. K. Park, S. B. Lee, and Y. M. Lee, Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 26, 1053 (2005).
64. J. A. Reddy, V. M. Allagadda, and C. P. Leamon, Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol. 6, 131 (2005).
65. H. Wartlick, K. Michaelis, S. Balthasar, K. Strebhardt, J. Kreuter, and K. Langer, Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target 12, 461 (2004).
66. Y. Aktas, M. Yemisci, K. Andrieux, R. N. Gursoy, M. J. Alonso, E. Fernandez-Megia, R. Novoa-Carballal, E. Quinoa, R. Riguera, M. F. Sargon, H. H. Celik, A. S. Demir, A. A. Hincal, R. Dalkara, Y. Capan, and P. Couvreur, Development. and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 16, 1503 (2005).
67. O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie, and R. Langer, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 103, 6315 (2006).
68. O. C. Farokhzad, J. M. Karp, and R. Langer, Nanoparticle-aptamer bioconjugates for cancer targeting. Expert. Opin. Drug Deliv. 3, 311 (2006).
69. D. Cunliffe, A. Kirby, and C. Alexander, Molecularly imprinted drug delivery systems. Adv. Drug Deliv. Rev. 57, 1836 (2005).
70. L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A. N. Fisher, and S. S. Davis, Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51, 81 (2001).
71. A. T. Florence, Issues in oral nanoparticle drug carrier uptake and targeting. J. Drug Target 12, 65 (2004).
72. C. Damgé, C. Michel, M. Aprahamian, and P. Couvreur, New approach for oral administration of insulin with polyalkyl-cyanoacrylate nanocapsules: as drug carrier. Diabetes 37, 246 (1988).
73. P. J. Lowe and C. S. Temple, Calcitonin and insulin in isobutyl-cyanoacrylate nanocapsules: Protection against prosteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 46, 547 (1994).
74. L. R. Brown, Commercial challenges of protein drug delivery. Expert Opinion on Drug Delivery 2, 29 (2005).
75. M. Morishita and N. A. Peppas, Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11, 905 (2006).
76. G. Ponchel and J. Irache, Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34, 191 (1998).
77. H. Pinto-Alphandary, M. Aboubakar, D. Jaillard, P. Couvreur, and C. Vauthier, Visualization of insulin-loaded nanocapsules: In vitro and in vivo studies after oral administration to rats. Pharm. Res. 20, 1071 (2003).
78. P. Calvo, C. Remunan-Lopez, J. L. Vila-Jato, and M. J. Alonso, Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 14, 1431 (1997).
79. I. Behrens, A. I. Pena, M. J. Alonso, and T. Kisoel, Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: The effect of mucus on particle adsorption and transport. Pharm. Res. 19, 1185 (2002).
80. C. Pegro, D. Torres, and M. J. Alonso, The potential of chitosan for the oral administration of peptides. Expert Opin. Drug Deliv. 2, 843 (2005).
81. I. Betholon, G. Ponchel, D. Labarre, P. Couvreur, and C. Vauthier, Bioadhesive properties of poly(alkylcyanoacrylate) nanoparticles coated with polysaccharide. J. Nanosci. Nanotechnol. 6, 3102 (2006).
82. I. Bravo-Osuna, C. Vauthier, A. Favabollini, G. F. Palmieri, and G. Ponchel, Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 28, 2233 (2007).
83. F. De Jaeghere, E. Allemann, F. Kubel, B. Gilli, R. Cozens, E. Doelker, and R. Gurny, Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: Effect of the particle size and nutritional state. J Control. Release 68, 291 (2000).
84. A. Bernkop-Schnurch, M. H. Hoffer, and K. Kafedjiiski, Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin. Drug Deliv. 1, 87 (2004).
85. A. T. Florence, Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Disc. Today Techn. 2, 75 (2005).
86. A. T. Florence, The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual. Pharm. Res. 14, 259 (1997).
87. A. Bernkop-Schnurch, A. H. Krauland, V. M. Leitner, and T. Palmberger, Thiomers: Potential excipients for non-invasive peptide delivery systems. Eur. J. Pharm. Biopharm. 58, 253 (2004).
88. I. Bravo-Osuna, C. Vauthier, and G. Ponchel, Characterization of chitosan and thiolated chitosan-coated cyanoacrylic nanoparticles intended for the improvement of drug intestinal absorption. Proceed. 33rd Annual meeting of the Controlled Release Society, Vienna, Austria, Abstract#319 (2006).
89. I. Bravo, C. Vauthier, A. Farabollini, G. Millotti, and G. Ponchel, In vitro antiprotease activity of chitosan and thiolated chitosan poly(isobutylcyanoacrylate) core shell nanoparticles. Submitted for publication.
90. P. Couvreur, B. Kante, L. Grislain, M. Roland, and P. Speiser, Toxicity of polyalkycyanoacrylate nanoparticles. II. Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 71, 790 (1982).
91. S. A. Wissing, O. Kayser, and R. H. Muller, Solid. lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257 ( 2004).
92. V. C. Mosqueira, P. M. Loiseau, C. Bories, P. Legrand, J. P. Devissaguet, and G. Barratt, Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium, berghei-infected mice. Antimicrob. Agents Chemother. 48, 1222 ( 2004).
93. A. Colin de Verdiére, C. Dubernet, F. Némati, E. Soma, M. Appel, J. Ferté, S. Bernard, F. Puisieux, and P. Couvreur, Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action. Br. J. Cancer 76, 198 (1997).
94. A. Colin de Verdiére, C. Dubernet, F. Némati, M. F. Poupon, F. Puisieux, and P. Couvreur, Uptake of doxorubicin from loaded nanoparticles in multidrug resistant leukemic murine cells. Cancer Chemother. Pharmacol. 33, 504 (1994).
95. L. Barraud, P. Merle, E. Soma, L. Lefrançois, S. Guerret, M. Chevallier, C. Dubernet, P. Couvreur, C. Trepo, and L. Vitvitski, Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42, 736 (2003).
96. N. Duzgunes, S. Simoes, V. Slepushkin, E. Pretzer, E. De Clerq, V. P. Antao, M. L. Collins, and M. C. Pedroso de Lima, Enhanced inhibition of HIV-1 replication in macrophages by anti-sense oligonucleotides, rybozymes and acyclic nucleoside phosphonate analogs delivered in pH sensitive liposomes. Nucleosides, Nucleotides Nucleic Acid. 20, 515 (2001).
97. R. M. Schiffelers, M. C. Woodle, and P. Scaria, Pharmaceutical prospects for RNA interference. Pharm. Res. 21, 1 (2004).
98. A. Sparreboom, S. D. Baker, and J. Verweij, Paclitaxel repackaged in an albumin-stabilized nanoparticle: Handy or just a dandy? J. Clin. Oncol. 23, 7765 (2005).
99. A. Moreno-Aspitia and E. A. Perez, Nanoparticle albumin-bound paclitaxel (ABI-007): A newer taxane alternative in breast cancer. Future Oncol. 1, 755 (2005).
100. S. Maillard, T. Ameller, J. Gauduchon, A. Gougelet, F. Gouilleux, P. Legrand, V. Marsaud, E. Fattal, B. Sola, and J. M. Renoir, Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J. Steroid. Biochem. Mol. Biol. 94, 111 (2005).
101. Y. de Kozak, K. Andrieux, H. Villaroya, C. Klein, B. Thillaye-Goldenberg, M. C. Naud, E. Garcia, and P. Couvreur, Intraocular injection of tamoxifen-loaded nanoparticles: A new treatment of experimental autoimmune uveoretinitis. Europ. J. Immunol. 34, 3702 (2004).
102. H. Boudad, P. Legrand, M. Appel, M. H. Coconier, and G. Ponchel, Formulation and cytotoxicity of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on caco-2 cells monolayers intended for oral administration of saquinavir, S.T.P. Pharma. Sci. 11, 369 (2001).
103. S. Peltier, J. M. Oger, F. Lagarce, W. Couet, and J. P. Benoit, Enhanced oral Paclitaxel bioavailability after administration of Paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23, 1243 ( 2006).
104. E. Fattal, B. Roques, F. Puisieux, M. J. Blanco-Prieto, and P. Couvreur, Multiple emulsion technology for the design of micro-spheres containing peptides and oligopeptides. Adv. Drug Deliv. Rev. 28, 85 (1997).
105. A. Maksimenko, C. Malvy, G. Lambert, J. R. Bertrand, E. Fattal, J. Maccario, and P. Couvreur, Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies. Pharm. Res. 20, 1565 (2003).
106. Y. Kakizawa, S. Furukawa, and K. Kataoka, Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligonucleotides and siRNA delivery. J Control. Release 97, 345 (2005).
107. J. L. Marchal-Heussler, P. Maincent, A Hoffman, J. Spittler, and P. Couvreur, Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutyl-cyanoacrylate preparations. Int. J. Pharm. 58, 115 (1990).
108. Y. Nakada, E. Fattal, M. Foulquier, and P. Couvreur, Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto polyisobutylcyanoacrylate nanoparticles after intravenous administration in mice. Pharm. Res. 13, 38 (1995).
109. F. Checot, A. Brulet, J. Oberdisse, J. Gnanou, O. Mondain-Monval, and S. Lecommandoux, Structure of polypeptide-based diblock copolymers in solution: Stimuli-responsive vesicles and micelles. Langmuir 21, 4308 (2005).
110. L. Y. Qiu and Y. H. Bae, Polymer architecture and drug delivery. Pharm. Res. 23, 1 (2006).
111. T. Pellegrino, S. Kudera, T. Liedl, A. Munoz Javier, L. Manna, and W. J. Parak, On the development of colloidal nanoparticles towards multifunctional structures and their possivle use for biological applications. Small 1, 48 (2005).
112. P. Couvreur, B. Stella, L. Harivardhan Reddy, H. Hillaireau, C. Dubernet, D. Desmaële, S. Lepêtre-Mouelhi, F. Rocco, N. Dereuddre-Bosquet, P. Clayette, V. Rosilio, V. Marsaud, M. Renoir, and L. Cattel, qualenoyl, Nanomedicines as potential therapeutics. Nano Lett. 6, 2544 (2006).